๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Cholangiocarcinoma
Clinical trial register · China

Cholangiocarcinoma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Hangzhou 6 Chengdu 4 Shanghai 4 Wuhan 2 Guangzhou 2
Narrow the registerReset
Recruitment status
Phase
Site location
Hangzhou6 Chengdu4 Shanghai4 Wuhan2 Guangzhou2
All 10 locations
Target enrolment
to

Cholangiocarcinoma trials in China

18 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study
NCT07729917Bile Duct Carcinoma, Cholangiocarcinoma
Zhejiang University
Phase 2
240
Hangzhou
2026-08-10
Recruiting
Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
NCT07641036Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma
Beijing Biotech
Phase 1/2
30
Shenzhen
2026-03-02
Recruiting
PULSAR Combined With Immunotherapy and Chemotherapy
NCT07291947Cholangiocarcinoma
Wang Xin
Phase 1/2
60
Chengdu
2025-11-04
Recruiting
Mechanistic Study on the Protective and Regenerative Effects of Spirulina in Hepatectomy-Related Liver Injury
NCT07263217Cholangiocarcinoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
30
Hangzhou
2025-10-01
Recruiting
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
NCT07106827HCC - Hepatocellular Carcinoma, Cholangiocarcinoma, Melanoma, NSCLC (Non-small Cell Lung Cancer)
West China Hospital
Phase 1
10
Chengdu
2025-09-04
Recruiting
Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma
NCT07105852Cholangiocarcinoma
Sir Run Run Shaw Hospital
Phase 2
59
Hangzhou
2025-07-03
Recruiting
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
NCT07030140Cholangiocarcinoma, Hilar Cholangiocarcinoma, Bile Duct Cancer
Jinbo Yue
Phase 2
38
Jinan
2025-07-01
Recruiting
Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer
NCT07025174Bile Duct Carcinoma, Gall Bladder Cancer, Biliary Tract Cancer, Cholangiocarcinoma
First Affiliated Hospital of Zhejiang University
Phase 2
60
Hangzhou
2025-06-01
Not yet open
A Novel Serological Risk Model for Early Non-invasive Diagnosis of Cholangiocarcinoma
NCT06658587Cholangiocarcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
60
Guangzhou
2024-11-01
Recruiting
Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma
NCT06718257Cholangiocarcinoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
300
Hangzhou
2024-09-01
Recruiting
Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma
NCT06438822Cholangiocarcinoma
West China Hospital
Phase 2
51
Chengdu
2024-08-30
Recruiting
Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA
NCT07291063Cholangiocarcinoma
Shanghai Zhongshan Hospital
Observational
50
Shanghai
2024-07-19
By invitation
Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)
NCT06963060Gallbladder Cancer, Cholangiocarcinoma
Wei Gong
Phase 2
44
Shanghai
2024-06-01
Recruiting
Bile Omics for Diagnosing Indeterminate Biliary Strictures
NCT07007832Cholangiocarcinoma, Gallbladder Cancer and Extrahepatic Cholangiocarcinoma, Pancreatic Cancer, Bile Duct Strictures of Unknown Origin
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Observational
260
Shanghai
2024-01-01
Active, closed
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
NCT04521686Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
Eli Lilly and Company
Phase 1
200
2020-10-01
Active, closed
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
NCT02568267Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms
Hoffmann-La Roche
Phase 2
534
Harbin, Wuhan, Chengdu, Beijing, Guangzhou, Hangzhou, Shanghai, Shenzhen
2015-11-19
Active, closed
Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma
NCT02482454Cholangiocarcinoma
The First People's Hospital of Changzhou
Phase 2/3
50
Changzhou
2012-07
Rows per page Showing 1–18 of 18
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/cholangiocarcinoma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 18 of those studies listing the condition Cholangiocarcinoma.

How many Cholangiocarcinoma trials are recruiting in China?

12 of the 18 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 3 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Cholangiocarcinoma), 18 studies
PhaseStudiesRecruitingShare
Phase 28544.4%
Observational4322.2%
Phase 12111.1%
Phase 1/22211.1%
Not applicable115.6%
Phase 2/3105.6%

Most active sponsors

Lead sponsors with the most studies (Cholangiocarcinoma)
Lead sponsorStudiesRecruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine22
West China Hospital22
Beijing Biotech11
Eli Lilly and Company10
First Affiliated Hospital of Zhejiang University11
Hoffmann-La Roche10
Jinbo Yue11
Liu Huang11
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine11
Shanghai Zhongshan Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.